Skip to content

Clinical study to evaluate efficacy and safety in health & immunity related parameters of Dabur Ratnaprash formulation

A two arm randomized, open labeled, prospective, multi-centre, clinical study to evaluate efficacy and safety of Dabur Ratnaprash in health & immunity related parameters

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/07/004804
Enrollment
100
Registered
2014-07-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Dabur Ratnaprash: Dabur Ratnaprash is a chyawanprash like formulation with multiple Ayurvedic ingredients mainly comprising of herbs. It is nutritious and good for health & well being a

Sponsors

Dabur India Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Male and female subjects aged 18 to 60 years (both the ages inclusive) •Ready to provide written informed consent •No history of any known allergy with Chyawanprash like products or any of the ingredientts of the Ratnaprash •Willing to come for the follow up visits for evaluation

Exclusion criteria

Exclusion criteria: •Presence of clinically significant abnormal laboratory, ECG or X-ray findings during screening. •Patients with known uncontrolled diabetes mellitus (DM), hypertension (HT), symptomatic congestive heart failure (CHF), unstable angina pectoris, myocardial infarction (MI) •Patients participated in another clinical drug trial within 3 months before recruitment in this trial •Any other medical condition that in the Investigators opinion would preclude patient participation •Pregnant and breast feeding women and women of child bearing age refusing to use contraceptive measures •Immunologically compromised individuals

Design outcomes

Primary

MeasureTime frame
Assessment of quality of life (QoL) and number of episodes, severity and duration of illness during the study periodTimepoint: 90 days (3 months)

Secondary

MeasureTime frame
To assess level of Energy and overall health status, physical fitness, level of endurance or stamina and physical strength, level of stress, Physicianâ??s Global evaluation, Laboratory parameters for safety and immunity and PalatabilityTimepoint: 90 days (3 months)

Countries

India

Contacts

Public ContactDr Sanjay Tamoli

Dabur India Limited

arun.gupta@dabur.com0120-3378614

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026